Hyperbaric oxygenation therapy for cyclophosphamide-induced haemorrhagic cystitis. 1995

H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
Department of Urology, Yamagata University School of Medicine, Japan.

A 41-year-old female patient undergoing cyclophosphamide therapy for ovarian tumour suffered from haemorrhagic cystitis. Hyperbaric oxygenation (HBO) (100% of oxygen concentration at 2 atmospheric absolute pressures for 60 minutes a day for 30 days) was performed. After treatment the symptom subsided and haematuria disappeared. Cystoscopic findings demonstrated marked improvement. During the course of therapy no side effect was noted. Thus, HBO treatment appeared to have a beneficial effect on cyclophosphamide cystitis.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003556 Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain. Cystitides
D005260 Female Females
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006931 Hyperbaric Oxygenation The therapeutic intermittent administration of oxygen in a chamber at greater than sea-level atmospheric pressures (three atmospheres). It is considered effective treatment for air and gas embolisms, smoke inhalation, acute carbon monoxide poisoning, caisson disease, clostridial gangrene, etc. (From Segen, Dictionary of Modern Medicine, 1992). The list of treatment modalities includes stroke. Oxygenation, Hyperbaric,Hyperbaric Oxygen Therapy,Hyperbaric Oxygen Therapies,Hyperbaric Oxygenations,Oxygen Therapies, Hyperbaric,Oxygen Therapy, Hyperbaric,Oxygenations, Hyperbaric,Therapies, Hyperbaric Oxygen,Therapy, Hyperbaric Oxygen
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D018906 Antineoplastic Agents, Alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) Alkylating Agents, Antineoplastic,Alkylating Antineoplastic Agents,Alkylating Antineoplastic Drugs,Alkylating Antineoplastics,Alkylating Drugs, Antineoplastic,Antineoplastic Alkylating Agents,Antineoplastic Drugs, Alkylating,Antineoplastics, Alkylating,Antineoplastic Alkylating Drugs,Drugs, Antineoplastic Alkylating

Related Publications

H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
August 2011, The New Zealand medical journal,
H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
July 2005, BJU international,
H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
November 2002, British journal of haematology,
H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
August 2002, International journal of urology : official journal of the Japanese Urological Association,
H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
January 1992, European urology,
H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
January 1998, Medical journal, Armed Forces India,
H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
August 2004, The Journal of urology,
H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
November 1963, Lancet (London, England),
H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
December 1963, Lancet (London, England),
H Yazawa, and T Nakada, and I Sasagawa, and M Miura, and Y Kubota
September 1971, The Medical journal of Australia,
Copied contents to your clipboard!